Consilium Strategic Communications is advising pharma business Shield Therapeutics on its proposed listing on London’s AIM market, following the company’s recent successful raising of £32.5 million.
Shield announced that it had raised the funds on Friday (12 February) from an issue of shares and warrants. It expects to start trading on London’s junior market on 26 February with a market capitalisation of £162m.
The Consilium team, made up of Mary-Jane Elliott, Matthew Neal, Lindsey Neville and Hendrik Thys, will continue to advise Shield on its financial comms and investor relations as a publicly listed company.
Carl Sterritt, founder and CEO of Shield, said: “Consilium provided us with trustworthy tactical advice, an enormous amount of relevant experience and an unparalleled capital markets network. We have enjoyed working with the proactive team and thank them for their contribution to our achievements to date.”
Elliott said: “Consilium has worked with Shield Therapeutics since 2010 and are pleased to have played a key role in the Company’s entrance to AIM. Shield is a high quality speciality pharma company with near-term revenue potential and a major market opportunity, addressing an unmet need for patients.”